Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use

References

• Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91:986–989.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. Invasive Aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2006;95:644–650.
   Google Scholar
• Nosari AM, Caira M, Pioltelli ML, Fanci R, Bonini A, Cattaneo C, et al. Hema e-Chart Group, Italy. Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. Clin Microbiol Infect. 2013;19:757–762.10.1111/1469-0691.12014
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality—SEIFEM-C report. Clin Infect Dis. 2007;44:1524–1525.10.1086/517849
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 2010;61:259–265.10.1016/j.jinf.2010.06.018
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45:1161–1170.10.1086/522189
   PubMed Web of Science ®Google Scholar
• Maertens J, Buvé K, Theunissen K, Meersseman W, Verbeken E, Verhoef G, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive Aspergillosis in neutropenic hematology patients. Cancer. 2009;115:355–362.10.1002/cncr.24022
   PubMed Web of Science ®Google Scholar
• Martino R, Kerguelen A, Valcárcel D, Sureda A, Fachini L, Piñana JL, et al. Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. Bone Marrow Transplant. 2011;46:690–701.10.1038/bmt.2010.177
   PubMed Web of Science ®Google Scholar
• Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:872–880.10.1016/j.bbmt.2014.03.004
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, et al. Infectious disease group of the EORTC. An EORTC phase II study of caspofungin as first-line therapy of invasive Aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64:1274–1281.10.1093/jac/dkp355
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, et al. Caspofungin first-line therapy for invasive Aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant. 2010;45:1227–1233.10.1038/bmt.2009.334
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive Aspergillosis. N Engl J Med. 2002;347(408):415.
   Google Scholar
• Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev. 2010;24:51–61.10.1016/j.blre.2009.11.003
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–5118.10.1182/blood-2010-02-268151
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318–327.10.1111/j.1365-2141.2011.08838.x
   PubMed Web of Science ®Google Scholar
• Bellmann R, Cleary JD, Sterba J. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. Clin Adv Hematol Oncol. 2009;7(4):1–8.
   PubMedGoogle Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–934.10.1007/s40265-013-0069-4
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect. 2008;14(Suppl. 4):25–36.10.1111/j.1469-0691.2008.01979.x
   PubMed Web of Science ®Google Scholar
• Lanternier F, Lortholary O. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect. 2008;14(Suppl. 4):71–83.10.1111/j.1469-0691.2008.01984.x
   PubMed Web of Science ®Google Scholar
• Worth LJ, Blyth CC, Booth DL, Kong DC, Marriott D, Cassumbhoy M, et al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern Med J. 2008;38(6b):521–537.10.1111/imj.2008.38.issue-6b
   PubMed Web of Science ®Google Scholar
• Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008;61(1):17–25.
   PubMed Web of Science ®Google Scholar
• Smith J, Andes DA. Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167–172.10.1097/FTD.0b013e318167d0e0
   PubMed Web of Science ®Google Scholar
• Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome(®)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76(4):485–500.
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4(1):1–23.
   PubMed Web of Science ®Google Scholar
• Bellocchio S, Gaziano R, Bozza S, Rossi G, Montagnoli C, Perruccio K, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother. 2005;55(2):214–222.10.1093/jac/dkh542
   PubMed Web of Science ®Google Scholar
• Candoni A, Aversa F, Busca A, Cesaro S, Girmenia C, Luppi M, et al. Combination antifungal therapy for invasive mould diseases in haematologic patients: an update on clinical data. J Chemother. 2015 Feb;27(1):1–12.10.1179/1973947814Y.0000000224
   PubMed Web of Science ®Google Scholar
• Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R, et al. Survey of antifungal combination therapy for treatment of proven or probable invasive fungal diseases in Italian haematological centres. The seifem-combo study. Mycoses. 2014;57(6):342–350.
   PubMed Web of Science ®Google Scholar
• Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al. Liposomal amphotericin B in combination with caspofungin for invasive Aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110:2740–2746.10.1002/cncr.v110:12
   PubMed Web of Science ®Google Scholar
• Jambor WP, Steinberg BA, Suydam LO. Amphotericins A and B: two new antifungal antibiotics possessing high activity against deep-seated and superficial mycoses. Antibiot Annu. 1955–1956;3:574–578.
   PubMedGoogle Scholar
• Kamiński DM. Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments. Eur Biophys J. 2014;43(10–11):453–467.10.1007/s00249-014-0983-8
   PubMed Web of Science ®Google Scholar
• Baginski M, Resat H, Borowski E. Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta. 2002;1567(1–2):63–78.10.1016/S0005-2736(02)00581-3
   PubMed Web of Science ®Google Scholar
• Readio JD, Bittman R. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochim Biophys Acta. 1982;685(2):219–224.10.1016/0005-2736(82)90103-1
   PubMed Web of Science ®Google Scholar
• Shimizu K, Osada M, Takemoto K, Yamamoto Y, Asai T, Oku N. Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane. J Control Release. 2010;141(2):208–215.10.1016/j.jconrel.2009.09.019
   PubMed Web of Science ®Google Scholar
• Takemoto K, Kanazawa K. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy. J Liposome Res. 2016 Jul;74:1–9.10.1080/08982104.2016.1205087
   Google Scholar
• Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect. 2008;14(Suppl. 4):55–64.
   PubMed Web of Science ®Google Scholar
• Storm G, van Etten E. Biopharmaceutical aspects of lipid formulations of amphotericin B. Eur J Clin Microbiol Infect Dis. 1997;16(1):64–73.10.1007/BF01575123
   PubMed Web of Science ®Google Scholar
• Lewis RE. Pharmacodynamic implications for use of antifungal agents. Curr Opin Pharmacol. 2007;7(5):491–497.10.1016/j.coph.2007.05.004
   PubMed Web of Science ®Google Scholar
• Khoo SH, Bond J, Denning DW. Administering amphotericin B – a practical approach. J Antimicrob Chemother. 1994;33(2):203–213.10.1093/jac/33.2.203
   PubMed Web of Science ®Google Scholar
• Falci DR, da Rosa FB, Pasqualotto AC. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study. Mycoses. 2015 Feb;58(2):104–112.10.1111/myc.2015.58.issue-2
   PubMed Web of Science ®Google Scholar
• Falci DR, da Rosa FB, Pasqualotto AC. Hematological toxicities associated with amphotericin B formulations. Leuk Lymphoma. 2015;56(10):2889–2894.10.3109/10428194.2015.1010080
   PubMed Web of Science ®Google Scholar
• Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood. 2006;107:916–923.
   PubMed Web of Science ®Google Scholar
• Andes D. Pharmacokinetics and Pharmacodynamics of antifungals. Infect Dis Clin North Am. 2006;20(3):679–697.10.1016/j.idc.2006.06.007
   PubMed Web of Science ®Google Scholar
• Venisse N, Gregoire N, Marliat M, Couet W. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob Agents Chemother. 2008;52(3):937–943.10.1128/AAC.01030-07
   PubMed Web of Science ®Google Scholar
• Di Bonaventura G, Spedicato I, Picciani C, D’Antonio D, Piccolomini R. In Vitro pharmacodynamic characteristics of amphotericin B, Caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother. 2004;48(11):4453–4456.10.1128/AAC.48.11.4453-4456.2004
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000;44(4):1108–1111.10.1128/AAC.44.4.1108-1111.2000
   PubMed Web of Science ®Google Scholar
• Andes D, Safdar N, Marchillo K, Conklin R. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother. 2006;50(2):674–684.10.1128/AAC.50.2.674-684.2006
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary Aspergillosis. Antimicrob Agents Chemother. 2006;50(2):469–473.10.1128/AAC.50.2.469-473.2006
   PubMed Web of Science ®Google Scholar
• Hong Y, Shaw PJ, Tattam BN, Nath CE, Earl JW, Stephen KR, et al. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. Eur J Clin Pharmacol. 2007;63(2):165–172.10.1007/s00228-006-0240-x
   PubMed Web of Science ®Google Scholar
• Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, et al. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an In Vitro model of invasive pulmonary Aspergillosis. Antimicrob Agents Chemother. 2010;54(8):3432–3441.10.1128/AAC.01586-09
   PubMed Web of Science ®Google Scholar
• Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69(3):361–392.10.2165/00003495-200969030-00010
   PubMed Web of Science ®Google Scholar
• Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57(6):1153–1160.10.1093/jac/dkl141
   PubMed Web of Science ®Google Scholar
• Demartini G, Lequaglie C, Brega massone PP, Scaglione F, Fraschini F. Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion. J Chemother. 2005;17(1):82–85.10.1179/joc.2005.17.1.82
   PubMed Web of Science ®Google Scholar
• Watanabe A, Matsumoto K, Igari H, Uesato M, Yoshida S, Nakamura Y, et al. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome). Int J Infect Dis. 2010;14(Suppl 3):e220–e223.10.1016/j.ijid.2009.07.020
   Google Scholar
• Monforte V, Ussetti P, López R, Gavaldà J, Bravo C, de Pablo A, et al. Nebulized liposomal amphotericin B Prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28(2):170–175.10.1016/j.healun.2008.11.004
   PubMed Web of Science ®Google Scholar
• Fauvel M, Farrugia C, Tsapis N, Gueutin C, Cabaret O, Bories C, et al. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity. Int J Pharm. 2012;436(1–2):106–110.10.1016/j.ijpharm.2012.07.012
   PubMed Web of Science ®Google Scholar
• Strenger V, Meinitzer A, Donnerer J, Hofer N, Dornbusch HJ, Wanz U, et al. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. J Antimicrob Chemother. 2014;69(9):2522–2526.10.1093/jac/dku148
   PubMed Web of Science ®Google Scholar
• Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274–282.10.1086/jid.2000.182.issue-1
   PubMed Web of Science ®Google Scholar
• Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46(3):828–833.10.1128/AAC.46.3.828-833.2002
   PubMed Web of Science ®Google Scholar
• Gazzoni AF, Capilla J, Mayayo E, Guarro J. Efficacy of intrathecal administration of liposomal amphotericin B combined with voriconazole in a murine model of cryptococcal meningitis. Int J Antimicrob Agents. 2012;39:223–227.10.1016/j.ijantimicag.2011.10.014
   PubMed Web of Science ®Google Scholar
• Capilla J, Flavia AF, Mayayo E, Guarro J. Efficacy of intrathecal liposomal amphotericin B plus oral posaconazole in the treatment of acute meningeal cryptococcosis in a murine model. Int J Antimicrob Agents. 2013;282–283.10.1016/j.ijantimicag.2013.04.032
   PubMed Web of Science ®Google Scholar
• Grannan BL, Yanamadala V, Venteicher AS, Walcott BP, Barr JC. Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess. J Clin Neurosci. 2014;21(10):1819–1821.10.1016/j.jocn.2014.01.008
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. AmBiLoad trial study group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289–1297.10.1086/514341
   PubMed Web of Science ®Google Scholar
• El Cheikh Jean, Castagna Luca, Wang Ling, Esterni Benjamin, Faucher Catherine, Furst Sabine, et al. Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. Hematol Oncol Stem Cell Ther. 2010;3(4):167–173.10.5144/1658-3876.2010.167
   PubMedGoogle Scholar
• Luu Tran H, Mahmoudjafari Z, Rockey M, Henry D, Grauer D, Aljitawi O, et al. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. J Oncol Pharm Pract. 2016 Apr;22(2):228–234.10.1177/1078155214560920
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C. In vitro susceptibility testing in Aspergillus species: an update. Future Microbiol. 2010 May;5(5):789–799.10.2217/fmb.10.34
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Prigitano A, Dho G, Biraghi E, Stevens DA, Ghannoum M, et al. In Vitro activity of amphotericin B against Aspergillus terreus isolates from different countries and regions. J Chemother. 2008;20:756–757.10.1179/joc.2008.20.6.756
   PubMed Web of Science ®Google Scholar
• Alastruey-Izquierdo A, Melhem MS, Bonfietti LX, Rodriguez-Tudela JL. Susceptibility test for fungi: clinical and laboratorial correlations in medical mycology. Rev Inst Med Trop Sao Paulo. 2015 Sep;57(Suppl 19):57–64.10.1590/S0036-46652015000700011
   PubMed Web of Science ®Google Scholar
• Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49(Suppl 1):7–10.10.1093/jac/49.suppl_1.7
   PubMed Web of Science ®Google Scholar
• Canuto MM, Rodero FG. Antifungal drug resistance to azoles and polyenes. Lancet Infect Disease. 2002;2:550–563.10.1016/S1473-3099(02)00371-7
   PubMed Web of Science ®Google Scholar
• Molzahn SW, Woods RA. Polyene resistance and the isolation of sterol mutants in saccharomyces cerevisiae. J Gen Microbiol. 1972;72:339–348.10.1099/00221287-72-2-339
   PubMedGoogle Scholar
• Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front Microbiol. 2012;3:286–286.
   PubMedGoogle Scholar
• Espinel-Ingroff A, Turnidge J. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Rev Iberoam Micol. 2016 Apr–Jun;33(2):63–75.10.1016/j.riam.2016.04.001
   PubMed Web of Science ®Google Scholar
• Hachem R, Gomes MZ, El Helou G, El Zakhem A, Kassis C, Ramos E, et al. Invasive Aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy. J Antimicrob Chemother. 2014;69:3148–3155.10.1093/jac/dku241
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, et al. Clinical epidemiology of 960 patients with invasive Aspergillosis from the PATH Alliance registry. J Infect. 2012;65:453–464.10.1016/j.jinf.2012.08.003
   PubMed Web of Science ®Google Scholar
• Rüping MJGT, Gerlach S, Fischer G, Lass-Flörl C, Hellmich M, Vehreschild JJ, et al. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study. J Hosp Infect. 2011;78:226–230.10.1016/j.jhin.2011.01.020
   PubMed Web of Science ®Google Scholar
• Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from italian patients treated for haematological malignancies. Int J Antimicrob Agents. 2012 May;39(5):440–443.10.1016/j.ijantimicag.2012.01.013
   PubMed Web of Science ®Google Scholar
• Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15:1068–1076.10.3201/eid1507.090043
   PubMed Web of Science ®Google Scholar
• Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat. 2005;8(6):344–358.10.1016/j.drup.2006.01.001
   PubMed Web of Science ®Google Scholar
• Hof H. Critical Annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother. 2001;45(11):2987–2990.10.1128/AAC.45.11.2987-2990.2001
   PubMed Web of Science ®Google Scholar
• van der Linden JWM, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus , the Netherlands, 2007–2009. Emerg Infect Dis. 2011;17:1846–1854.10.3201/eid1710.110226
   PubMed Web of Science ®Google Scholar
• Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12(6):141–147.10.1016/j.drup.2009.09.002
   PubMed Web of Science ®Google Scholar
• van Ingen J, van der Lee HA, Rijs TA, Zoll J, Leenstra T, Melchers WJ, et al. Azole, polyene and echinocandin MIC distributions for wild-type TR34/L98H and TR46/Y121F/T298A Aspergillus fumigatus isolates in the Netherlands. JAC. 2015;70:178–181.
   Google Scholar
• Steinmann J, Hamprecht A, Vehreschild MJGT, Cornely OA, Buchheidt D, Spiess B, et al. Emergence of azole-resistant invasive Aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015;70:1522–1526.10.1093/jac/dku566
   PubMed Web of Science ®Google Scholar
• van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013;57:513–520.10.1093/cid/cit320
   PubMed Web of Science ®Google Scholar
• Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci. 2015 Sep;1354:1–11.10.1111/nyas.2015.1354.issue-1
   PubMed Web of Science ®Google Scholar
• Segal BH, Kwon-Chung J, Walsh TJ, Klein BS, Battiwalla M, Almyroudis NG, et al. Immunotherapy for fungal infections. Clin Infect Dis. 2006;42(4):507–515.10.1086/499811
   PubMed Web of Science ®Google Scholar
• Schneider DS, Ayres JS. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol. 2008;8(11):889–895.10.1038/nri2432
   PubMed Web of Science ®Google Scholar
• Cobbold SP, Adams E, Nolan KF, Regateiro FS, Waldmann H. Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link. Immunol Rev. 2010;236:203–218.10.1111/j.1600-065X.2010.00913.x
   PubMed Web of Science ®Google Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181.10.1038/nri2711
   PubMed Web of Science ®Google Scholar
• Gupta AO, Singh N. Immune reconstitution syndrome and fungal infections. Curr Opin Infect Dis. 2011;24(6):527–533.10.1097/QCO.0b013e32834ab20a
   PubMed Web of Science ®Google Scholar
• Perfect JR. The impact of the host on fungal infections. Am J Med. 2012;125(1):S39–S51.10.1016/j.amjmed.2011.10.010
   Google Scholar
• Ortega M, Rovira M, Filella X, Martínez JA, Almela M, Puig J, et al. Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37(5):499–502.10.1038/sj.bmt.1705262
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Bozza S, Moretti S, Massi-Benedetti C, Bistoni F, et al. Immunity and tolerance to fungi in hematopoietic transplantation: principles and perspectives. Front Immunol. 2012;3(article156):1–8.
   PubMedGoogle Scholar
• Hontelez S, Sanecka A, Netea MG, van Spriel AB, Adema GJ. Molecular view on PRR cross-talk in antifungal immunity. Cell Microbiol. 2012;14(4):467–474.10.1111/j.1462-5822.2012.01748.x
   PubMed Web of Science ®Google Scholar
• Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin b promotes inflammatory cytokine release by a toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003;278(39):37561–37568.
   PubMed Web of Science ®Google Scholar
• Lacerda JF, Oliveira CM. Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B. Clin Drug Investig. 2013;33(S1):5–14.10.1007/s40261-012-0023-3
   Web of Science ®Google Scholar
• Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J Control Release. 2012;161(2):600–608.10.1016/j.jconrel.2011.12.034
   PubMed Web of Science ®Google Scholar
• Zolnik BS, González-Fernández África, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology. 2010;151(2):458–465.10.1210/en.2009-1082
   PubMed Web of Science ®Google Scholar
• Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007;7(10):817–823.10.1038/nri2163
   PubMed Web of Science ®Google Scholar
• Gaziano R, Bozza S, Bellocchio S, Perruccio K, Montagnoli C, Pitzurra L, et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother. 2004;48(11):4414–4421.10.1128/AAC.48.11.4414-4421.2004
   PubMed Web of Science ®Google Scholar
• Cunha C, Aversa F, Bistoni G, Casagrande A, Rodrigues F, Romani L, et al. Immunogenetic profiling to predict risk of invasive fungal diseases: where are we now? Immunol Invest. 2011;40(7–8):723–734.10.3109/08820139.2011.586395
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol. 2016;7(6):345–359.10.1177/2040620716656381
   PubMed Web of Science ®Google Scholar
• Lupiañez CB, Villaescusa MT, Carvalho A, Springer J, Lackner M, Sánchez-Maldonado JM, et al. Common genetic polymorphisms within NFκB-Related genes and the risk of developing invasive Aspergillosis. Front Microbiol. 2016;7:1243.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Carotti A, Aloisi T, Guarrera O, Di Ianni M, et al. Polymorphisms in toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. Exp Hematol. 2009;37:1022–1029.10.1016/j.exphem.2009.06.004
   PubMed Web of Science ®Google Scholar
• Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, et al. Genetic PTX3 deficiency and Aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370:421–432.10.1056/NEJMoa1211161
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high‐risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8):1042–1051.10.1086/599079
   PubMed Web of Science ®Google Scholar
• Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant. 2009;43(7):553–561.10.1038/bmt.2008.355
   PubMed Web of Science ®Google Scholar
• Freemantle N, Tharmanathan P, Herbrecht R. Systematic reviewand mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother. 2011;66(Supplement 1):i25–i35.10.1093/jac/dkq439
   Google Scholar
• Walsh TJ1, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225–234.10.1056/NEJM200201243460403
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391–1402.10.1056/NEJMoa040446
   PubMed Web of Science ®Google Scholar
• Martin MT, Gavaldà J, López P, Gomis X, Ramírez JL, Rodríguez D, et al. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental Aspergillosis. J Antimicrob Chemother. 2003;52(6):1032–1034.10.1093/jac/dkh003
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, et al. Pediatric invasive Aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121(5):e1286–e1294.10.1542/peds.2007-2117
   PubMed Web of Science ®Google Scholar
• Cugno C, Cesaro S. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep. 2012;4(1):9.10.4081/pr.2012.e9
   PubMedGoogle Scholar
• Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, et al. Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15(8):e327–e340.10.1016/S1470-2045(14)70017-8
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment ofinvasive candidiasis, Aspergillosis and mucormycosis in leukemia andhematopoietic stem cell transplant patients. Haematologica. 2016 Dec;23:101. pii: haematol.2016.152900. [Epub ahead of print] PubMed PMID: 28011902. DOI:10.3324/haematol.2016.152900.
   Google Scholar
• Döring M1, Hartmann U, Erbacher A, Lang P, Handgretinger R, Müller I. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis. 2012;12:e1286.10.1186/1471-2334-12-151
   Google Scholar
• Bochennek K, Tramsen L, Schedler N, Becker M, Klingebiel T, Groll AH, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin Microbiol Infect. 2011;17(12):1868–1874.10.1111/j.1469-0691.2011.03483.x
   PubMed Web of Science ®Google Scholar
• Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2006;12(2):235–240.10.1016/j.bbmt.2005.10.010
   PubMed Web of Science ®Google Scholar
• Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive Aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2014;28:80–94.10.1016/j.ijid.2014.07.007
   PubMed Web of Science ®Google Scholar
• Pagano L, Cornely OA, Busca A, Caira M, Cesaro S, Gasbarrino C, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–e130.10.3324/haematol.2012.083063
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis. 2012;54(Suppl 1):S73–S78.10.1093/cid/cir885
   PubMed Web of Science ®Google Scholar
• Panackal AA. Combination antifungal therapy for invasive Aspergillosis revisited. Med Mycol Open Access. 2016;2(2). pii: 12. Epub 2016 Apr 29.
   PubMedGoogle Scholar
• Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21–22:30–40.10.1016/j.drup.2015.08.001
   PubMed Web of Science ®Google Scholar
• van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21:1041–1044.10.3201/eid2106.140717
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive Aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89.10.7326/M13-2508
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive Aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–299.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025–1032.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive Aspergillosis. Cancer. 2005;103:2334–2337.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Rieger CT, Ostermann H, Kolb HJ, Fiegl M, Huppmann S, Morgenstern N, et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in hematological cancer patients. Ann Hematol. 2008;87(11):915–922.10.1007/s00277-008-0534-4
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Ratanatharathorn V, Young JA, Young JA, Raymond J, Laverdière M, et al. Micafungin alone or in combination with other systemic antifungal therapies in HSCT recipients with invasive Aspergillosis. Transpl Infect Dis. 2009;11:89–93.10.1111/tid.2009.11.issue-1
   PubMed Web of Science ®Google Scholar
• Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive Aspergillosis in hematological malignancy patients ? Cancer. 2010;116(22):5290–5296.10.1002/cncr.25312
   PubMed Web of Science ®Google Scholar
• Rojas R, Molina Josè R, Jarque I, Montes C, Serrano J, Sanz J, et al. Outcome of antifungal combination therapy for invasive mold infections in hematological patients is indipendent of the chosen combination. Med J Hem Infect Dis. 2012;4(1):e2012011.10.4084/mjhid.2012.011
   Google Scholar